SOPHiA GENETICS (SOPH) CMO sells 5,000 shares under 10b5-1 plan

Rhea-AI Filing Summary

SOPHiA GENETICS SA Chief Medical Officer Philippe Menu executed an open-market sale of 5,000 Ordinary Shares at a weighted average price of $4.8178 per share. Following this transaction, he directly holds 261,388 Ordinary Shares. The sale was made under a duly adopted Rule 10b5-1(c) trading plan.

Insights

Insider trading & governance analyst

CMO sells 5,000 SOPHiA GENETICS shares in small, pre-planned trade.

Philippe Menu, Chief Medical Officer of SOPHiA GENETICS SA, completed an open-market sale of 5,000 Ordinary Shares at a weighted average price of $4.8178 per share. The transaction is coded as an open-market sale (code S).

After the sale, Menu directly holds 261,388 Ordinary Shares, so the transaction reflects only a small fraction of his visible position, roughly about 2% of his holdings. The filing shows no derivative exercises and no remaining derivative positions in this excerpt.

A key detail is that the sale occurred pursuant to a Rule 10b5-1(c) trading plan, indicating it was pre-scheduled rather than timed opportunistically. The price was reported as a weighted average, with individual trades between $4.75 and $4.89 on April 27, 2026.

Insider Trade Summary 10b5-1

Net Seller: 5,000 shares ($24,089)

Net Sell 1 txn

Insider Menu Philippe

Role Chief Medical Officer

Sold 5,000 shs ($24K)

Type	Security	Shares	Price	Value
Sale	Ordinary Shares	5,000	$4.8178	$24K

Holdings After Transaction: Ordinary Shares — 261,388 shares (Direct, null)

Footnotes (1)

1. Transaction made pursuant to duly adopted trading plan under Rule 10b5-1(c). The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $4.75 to $4.89, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Key Figures

Shares sold: 5,000 shares Average sale price: $4.8178 per share Post-transaction holdings: 261,388 shares +1 more

4 metrics

Shares sold 5,000 shares Open-market sale of Ordinary Shares on April 27, 2026

Average sale price $4.8178 per share Weighted average sale price for 5,000 shares

Post-transaction holdings 261,388 shares Ordinary Shares directly owned after sale

Price range $4.75–$4.89 per share Range of prices for individual sale transactions

Key Terms

Rule 10b5-1(c), weighted average price, open-market sale, Ordinary Shares

4 terms

Rule 10b5-1(c) regulatory

"Transaction made pursuant to duly adopted trading plan under Rule 10b5-1(c)."

Rule 10b5-1(c) is an SEC guideline that lets company insiders set up a written, pre-planned schedule to buy or sell their company stock when they are not in possession of material, nonpublic information. For investors, it matters because such plans can reduce the appearance of insider trading by separating decisions from inside knowledge—like putting your trades on autopilot—while also requiring scrutiny since pre-planned trades can still affect market confidence and share value.

weighted average price financial

"The price reported in Column 4 is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

open-market sale financial

"transaction_action": "open-market sale""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Ordinary Shares financial

""security_title": "Ordinary Shares""

Ordinary shares are a type of ownership stake in a company, giving shareholders a right to participate in the company’s profits and decision-making through voting. They are similar to owning a piece of a business, and their value can rise or fall based on the company's performance. Investors buy ordinary shares to potentially earn dividends and benefit from the company's growth over time.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Menu Philippe

(Last) (First) (Middle)

C/O SOPHIA GENETICS SA

LA PIECE 12

(Street)

ROLLE 1180

(City) (State) (Zip)

SWITZERLAND

(Country)

2. Issuer Name and Ticker or Trading Symbol
SOPHiA GENETICS SA [ SOPH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/27/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	04/27/2026		S		5,000(1)	D	$4.8178(2)	261,388	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Transaction made pursuant to duly adopted trading plan under Rule 10b5-1(c).

2. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $4.75 to $4.89, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Remarks:

	/s/ Elimara Brunetto as Attorney-in-fact for Philippe Menu	04/28/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did SOPHiA GENETICS (SOPH) Chief Medical Officer sell in this Form 4?

The Chief Medical Officer, Philippe Menu, sold 5,000 Ordinary Shares of SOPHiA GENETICS SA. The transaction was an open-market sale at a weighted average price of $4.8178 per share, according to the Form 4 filing.

At what prices were SOPHiA GENETICS (SOPH) shares sold in this insider transaction?

The Form 4 reports a weighted average price of $4.8178 per share. Footnotes explain the shares were sold in multiple trades at prices ranging from $4.75 to $4.89, with the insider able to provide exact breakdowns on request.

How many SOPHiA GENETICS (SOPH) shares does the insider hold after this Form 4 sale?

After selling 5,000 shares, Chief Medical Officer Philippe Menu directly holds 261,388 Ordinary Shares of SOPHiA GENETICS SA. This post-transaction holding is disclosed in Column 5 of the Form 4 non-derivative securities table.

Was the SOPHiA GENETICS (SOPH) insider sale made under a Rule 10b5-1 trading plan?

Yes. A footnote states the transaction was made pursuant to a duly adopted Rule 10b5-1(c) trading plan. Such plans pre-schedule trades, indicating this sale was arranged in advance rather than timed in response to short-term market movements.

Does this SOPHiA GENETICS (SOPH) Form 4 include any option exercises or derivative transactions?

No derivative activity is shown in the provided data. The filing reports a single non-derivative open-market sale of 5,000 Ordinary Shares, and the derivativeSummary section is empty, indicating no option exercises or other derivative trades in this excerpt.